Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes.
Vous n'êtes pas connecté
Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes. In recent years, CAR-T cell therapies have become an essential part of the treatment of patients whose lymphoma or multiple myeloma has relapsed. This involves genetically modifying the patient’s T lymphocytes (T cells) to [...]
Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes.
Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene...
Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves...
A type of aggressive, treatment-resistant brain tumour has a distinct population of immune cells that support its growth, according to new research...
A new Moffitt Cancer Centre study has identified a specific immune response that may prevent the spread of breast cancer cells within the body....
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance...
The highest risk of dementia was found in people whose immune system aged faster than usual – not in people whose brains aged more rapidly.
Discover groundbreaking research showing that lungs, alongside bone marrow, play a crucial role in blood cell production, offering new insights for...
On February 11, 2025, the Food and Drug Administration approved brentuximab vedotin in combination with lenalidomide and a rituximab product for adult...
Cancer cells have special adaptation mechanisms that allow them to proliferate despite changes in their genetic makeup. Researchers at RPTU University...